Condensed Consolidated Statements of Operations - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2018	Jun. 30, 2017	Jun. 30, 2018	Jun. 30, 2017
Revenues
Royalty and licensing revenue	$ 3,053,000	$ 3,750,000	$ 4,702,000	$ 3,750,000
Treatment investment revenue	53,000	22,000	107,000	33,000
Grant revenue	44,000	0	44,043	0
Total revenue	3,150,000	3,772,000	4,853,000	3,783,000
Operating expenses
General and administrative	2,857,000	1,850,000	5,822,000	3,708,000
Research and development	1,616,000	1,383,000	4,036,000	2,272,000
License fees	0	0	5,625,000	0
Selling expenses	0	328,000	0	413,000
Total operating expenses	4,473,000	3,561,000	15,483,000	6,393,000
Income (loss) from operations	(1,323,000)	211,000	(10,630,000)	(2,610,000)
Other income (expense)
Interest income, net	6,000	12,000	11,000	21,000
Loss on settlement of liability	(50,000)	0	(50,000)	0
Gain (Loss) on foreign exchange	(30,000)	16,000	(38,000)	31,000
Total other income (expense)	(74,000)	28,000	(77,000)	52,000
Income (loss) before provision for income taxes	(1,397,000)	239,000	(10,707,000)	(2,558,000)
Provision for income taxes	0	0	33,000	0
Net income (loss)	$ (1,396,557)	$ 238,707	$ (10,740,195)	$ (2,557,952)
Net income (loss) per share of common stock:
Basic (in dollars per share)	$ (0.52)	$ 0.12	$ (4.11)	$ (1.27)
Diluted (in dollars per share)	$ (0.52)	$ 0.11	$ (4.11)	$ (1.27)
Weighted average shares outstanding used to compute net income (loss) per share:
Basic (in shares)	2,679,910	2,020,380	2,611,245	2,015,192
Diluted (in shares)	2,679,910	2,144,921	2,611,245	2,015,192